Research
Hormonal
Both resistin and visfatin act as pro-inflammatory mediators that contribute to chronic inflammatory diseases, including rheumatoid arthritis, atherosclerosis, and inflammatory bowel disease, by stimulating cytokine production and immune cell activation.
Resistin and visfatin are hormones that promote inflammation, which is linked to many chronic diseases. Reducing inflammation through diet and lifestyle may help manage these hormone levels and improve health outcomes in conditions like arthritis and heart disease.
GoodSupportsHIGH confidence
Despite the opposing effects of resistin and visfatin on the regulation of insulin sensitivity, both adipokines have pro-inflammatory properties. Clinical and experimental studies have shown that the expression and secretion of resistin and visfatin are up-regulated during inflammation and in response to pro-inflammatory cytokines.
Why this rating
Strong experimental and clinical evidence linking these adipokines to inflammatory processes in various diseases.
Source
Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity
Andrea Štofková · Endocrine Regulations · 2010
DOI 10.4149/endo_2010_01_25
narrative_reviewCited 193×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Resistin acts as a pro-inflammatory mediator that impairs insulin sensitivity through multiple mechanisms, including inhibition of glucose transporter activity, suppression of GLUT4 translocation, and activation of inflammatory pathways like NF-kappaB.Moderate
- Visfatin (also known as NAMPT or PBEF) exhibits insulin-mimicking effects in vitro by stimulating glucose uptake and insulin signaling pathways, but its physiological role in humans regarding insulin sensitivity remains controversial and unclear.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →